MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

    S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

    Objective: Evaluate magnitude of motor improvement with increasing doses of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease (PD) and OFF episodes. Background: Identifying…
  • 2022 International Congress

    Predictors of short-term anxiety outcome after subthalamic stimulation in Parkinson’s Disease

    A. Sauerbier, V. Stopic, J. Herberg, P. Loehrer, K. Ashkan, A. Rizos, S. Jost, JN. Petry-Schmelzer, S. Heil, A. Gronostay, M. Barbe, V. Visser-Vandewalle, J. Evans, C. Nimsky, G. Fink, A. Antonini, P. Martinez-Martin, M. Silverdale, D. Weintraub, A. Schrag, K. Ray Chaudhuri, L. Timmermann, H. Dafsari (Cologne, Germany)

    Objective: To identify clinical predictors of the effect of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s Disease (PD). Background: STN-DBS is a…
  • 2022 International Congress

    Gender-related sexual dysfunction in Parkinson disease: Clinical data of a hospital cohort in Tunisia

    L. Ali, H. Jamoussi, N. Ben Ali, S. Fray, M. Ben Mahmoud, M. Fredj (Tunis, Tunisia)

    Objective: Describe the nature of sexual dysfunctions (SD) associated to Parkinson disease (PD) in Tunisian patients. Identify gender related difference of SD in PD. Background:…
  • 2022 International Congress

    GDNF Gene Therapy for Parkinson’s Disease (PD): Preliminary Safety and Clinical Findings from a Phase Ib Study

    A. van Laar, C. Christine, A. Merola, N. Phielipp, B. Elder, P. Larson, N. Stoicea, W. San Sebastian, M. Fiandaca, A. Kells, K. Bankiewicz (Research Triangle Park, USA)

    Objective: Assess the safety and tolerability of intraputaminal AAV2-GDNF in mild to moderate PD Background: Glial cell line-derived neurotrophic factor (GDNF) is critical for dopaminergic…
  • 2022 International Congress

    A longitudinal evaluation of the peripheral immune phenotype in a cohort of Parkinson’s disease patients

    L. Magistrelli, A. Furgiuele, E. Contaldi, M. Legnaro, E. Rasini, C. Comi, F. Marino, M. Cosentino (Novara, Italy)

    Objective: To evaluate the suitable modifications of immunological parameters in a through characterized population of Italian PD patientsTo evaluate the suitable modifications of immunological parameters…
  • 2022 International Congress

    Short and long-term Impact of Covid-19 Pandemic on motor and non-motor symptoms in Leucine-rich repeat kinase2 (LRRK2) associated Parkinson’s disease

    A. Nasri, S. Mrabet, Y. Abida, A. Souissi, A. Gharbi, A. Gargouri, I. Kacem, R. Gouider (Tunis, Tunisia)

    Objective: To determine short and long-term impact of COVID-19 on motor(MS) and non-motor(NMS) symptoms among Tunisian PD patients according to Leucine-rich repeat kinase2 (LRRK2)-carrying status.…
  • 2022 International Congress

    Impact of COVID-19 in Parkinson disease: preliminary analysis from a survey performed in a Peruvian PD cohort.

    E. Sarapura-Castro, D. Rivera-Asencios, M. Illanes-Manrique, A. Rivera-Valdivia, M. Inca-Martinez, K. Mejia-Rojas, J. Rios-Pinto, A. Medina-Colque, I. Cornejo-Herrera, E. Ochoa-Valle, C. Cosentino, I. Mata, M. Cornejo-Olivas (Lima, Peru)

    Objective: To analyze the impact of COVID-19 in Parkinson cases and healthy controls from a Peruvian population. Background: The COVID-19 pandemic have a profound impact…
  • 2022 International Congress

    In-home remote assessment of the MDS-UPDRS Part III: multi-cultural development and validation of a guide for patients and care partners

    M. Tosin, A. Ferro, R. Wu, P. Rabano, P. Martinez-Martin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)

    Objective: To develop and validate a culturally-sensitive guide for the remote administration of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III.…
  • 2022 International Congress

    The study of clonidine growth hormone study amongst definite MSA, PD, PSP, and PAF patients to assess its feasibility as a future non-invasive biomarker

    S. Bhattacharjee, E. Vichayanrat, L. Watson, V. Iodice (London, United Kingdom)

    Objective: To analyze the sensitivity and specificity of the clonidine growth hormone (CGH) to distinguish probable multiple system atrophy (MSA) from pure autonomic failure (PAF),…
  • 2022 International Congress

    CORRELATION BETWEEN OLFACTORY DYSFUNCTION AND INTENSITY OF TREMOR

    D D. Pokhabov, V. Abramov, M. Sadovsky, D V. Pokhabov (Krasnoyarsk, Russian Federation)

    Objective: Our aim was to obtain tremor data of PD and ET patients and the results of their olfactory function, which can help verify our…
  • « Previous Page
  • 1
  • …
  • 196
  • 197
  • 198
  • 199
  • 200
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley